Akèy › Metiyè › Medical Scientists, Except Epidemiologists › Orlando, FL
Medical Scientists, Except Epidemiologists nan Orlando, FL: Salè H-1B
41 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Orlando, FL. Salè baz medyàn ofri $77,126; mwatye mitan $63,107–$95,472.
Demann (LCA)41
Salè medyan ofri$77,126
Mwatye salè yo$63,107–$95,472
10yèm–90yèm pousantaj$56,576–$119,288
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $59,002 |
| Nivo II (kalifye) | $77,657 |
| Nivo III (eksperyans) | $109,106 |
| Nivo IV (plen kompetans) | $72,040 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| Adventist Health System/Sunbelt, Inc. | 27 | $69,000 |
| University of Central Florida | 4 | $69,828 |
| AdventHealth University, Inc. | 2 | $90,292 |
| Certara USA Inc. | 2 | $140,804 |
| Orlando Health Inc. | 2 | $90,383 |
| University of Pittsburgh | 1 | $49,754 |
| Tabula Rasa HealthCare Group, Inc. | 1 | $138,921 |
| Hesperos, Inc. | 1 | $87,534 |
| University of Florida | 1 | $61,428 |
Tit travay
- Research Fellow7
- Orthopedic Senior Research Fellow4
- Associate Professor/Research Officer2
- Assistant Scholar/ Scientist of Medicine2
- Research Scientist - Neuroscience2
- Post-Doctoral Research Scientist2
- Research Scientist Postdoctoral Researcher2
- Research Scientist2
- Medical Research Analyst2
- Postdoctoral Researcher2
- Post-Doctoral Associate1
- Research Assistant Professor1
- Associate Clinical Scientist1
- Orthopedic Senior Research Fello1
- Orthopedic Research Fellow1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).